Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115). (2026) Klinghammer K, Graeven U, Ivanyi P, Dietz A, Hahn D, Hackenberg S, Kasper S, et al. Journal article Psychological Stress in Breast Cancer Patients during the Course of a Pandemic Disease: Before and after the Availability of Vaccines (2025) Schlaiß T, Vassilenko MD, Kimmel T, Diessner J, Wöckel A, McNeill R, Kittel-Schneider S, et al. Journal article Onkopedia: What’s New? Systemic Tumor Treatment in Pregnancy (2025) Maschmeyer G, Fehm T, Loibl S, Dittrich R, Hilgendorf I Journal article CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism (2025) Sinn M, Lohneis A, Mohamed O, Roderburg C, Hellmann M, Südhoff T, Christoph DC, et al. Journal article Treatment of Advanced or Metastatic Urothelial Cancer (2025) Hilser T, Darr C, Bedke J, Ivanyi P, Klümper N, Eckstein M, Schlack K, Grünwald V Journal article, Review article Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany (2024) Lugnier C, Sommerlatte S, Attenberger U, Beer AJ, Bentz M, Benz SR, Birkner T, et al. Journal article 36. Deutscher Krebskongress. Fortschritt gemeinsam gestalten, 21.–24. Februar 2024, Berlin: ABSTRACTS (2024) Büttner R Conference contribution Psycho-Oncological Self-Help Groups in Bavaria: The Current Situation and Suggestions for Improvement (2024) Lieb M, Madl M, Vogelhuber M, Beckmann M, Erim Y Journal article Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis (2023) Munker S, Roessler D, Öcal O, Ben-Khaled N, Bernhart K, Ye L, Piseddu I, et al. Journal article Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution